Inherited Pseudohypoaldosteronism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Inherited Pseudohypoaldosteronism. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Inherited Pseudohypoaldosteronism receives a directional score of 69/100, combining unmet need (83/100), competitive intensity (60/100) and market attractiveness (73/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A heterogeneous group of disorders characterized by renal electrolyte transport dysfunctions. Congenital forms are rare autosomal disorders characterized by neonatal hypertension, HYPERKALEMIA, increased RENIN activity and ALDOSTERONE concentration. The Type I features HYPERKALEMIA with sodium wasting; Type II, HYPERKALEMIA without sodium wasting. Pseudohypoaldosteronism can be the result of a defective renal electrolyte transport protein or acquired after KIDNEY TRANSPLANTATION.

The reproducible record is Patsnap disease ID 7bae596096e642d6a7f7284ec63f1521 and MeSH identifier D011546. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: The Prevalence of Sjögren’s Disease in Dental Clinics in the Netherlands Compared with the Prevalence in a Systematic Literature Review of Studies in Other Countries

The total population of subjects, investigated according to the AECG criteria, com- prised 4,158,123 individuals with a total pooled prevalence of 0.031%. The highest preva- lence in a study using the AECG diagnostic criteria was 0.72% in Turkey [40]. The lowest prevalence using the AECG was 0.01% in both France [32] and the USA [44]. The total population of individuals screened according to the EU criteria was 118,961 with a pooled prevalence of 0.029%, ranging from 0.22% in Norway [29] to 3.30% in the United King- dom [33]. The total number of subjects in seven studies with the ICD criteria comprised 94,663,803 individuals with a pooled prevalence of 0.048%, varying from 0.038% in Italy [34] to 0.12% in Colombia 7]. The single study from China that used the San Diego criteria reported a prevalence of 0.30% [43]. Figure 1. PRISMA flowchart of identification and selection of studies for inclusion. 3.3. Incidence Ratio of SjD Ten studies reported the incidence ratio of SjD [23,35,41,42,44,48–52] (Table 2). Four studies were performed in Asia [41,42,50,52], four in Europe [23,35,49,51] and two in the USA [44,48]. Of the included studies, three used AECG and one used the EU criteria. Four studies used International Classification of Diseases (ICD) codes, one study used a combination of ICD and ACR-EULAR criteria and one study did not report the diagnosis criteria used. Table 1. Overview of included Sjögren’s disease prevalence studies. Table 2. Overview of included Sjögren’s disease incidence studies. The overall study population was 118,356,435. The overall pooled incidence rate was 5.2 (95%CI 4.7 to 5.6) per 100,000 person-years. Two studies reported a change in incidence rate over time. Seror et al. [35] reported that the incidence rate declined in the period 2012–2017,

Review source

Epidemiology evidence 2: Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study

RESULTS The search identified 6772 studies through February 5, 2021, of which 405 were selected for full‐text review and 65 were included in our analysis: 17 reporting prevalence estimates, 17 reporting incidence, and 58 reporting case‐ fatality rate. Of these, 19 reported on more than one metric. All included studies were published between 1991 and 2021. See Figure 1 for the detailed flow of identified studies using a PRISMA‐style diagram. Thirty‐ seven countries and 22 registries were represented (Table 1). Four studies reported only pediatric cases. All studies, except for one, had >50% female cases. All studies with sex‐specific estimates of prevalence or in- cidence reported higher levels in females than males. The breakdown of subtypes within WHO group 1 PAH reported by studies is included in the Supporting In- formation Table. Reported prevalence ranged from 0.37 cases/ 100,000, in a referral center of French children, to 15 cases/100,000, in an Australian study of a large data- base of echocardiograms (Figure 2). The simple mean of reported prevalence was 3.0 cases/100,000. Twelve studies diagnosed PAH through RHC, one through echocardiography with optional RHC, one through echocardiography and RHC, and three with ICD codes. Two studies reported on primary pulmonary hy- pertension, while the rest reported on PAH. Restricting to studies diagnosing PAH with RHC, the simple mean of reported prevalence was 3.7 cases/100,000. Re- stricting to studies diagnosing PAH with ICD codes, the mean of reported prevalence was 1.6 cases/100,000, and reported prevalence ranged from 0.66 cases/ 100,000 to 3 cases/100,000.

Review source

Epidemiology evidence 3: Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database

were females. PBC was most commonly diagnosed in patients in their 50 to 60  s, with a mean of 57.8 ± 12.6 years. The 888 patients with PSC showed no sex domi­ nance and the mean age was 57.8 ± 21.5 years. Approxi­ mately half of AILD patients were classified in the 4th − 5th quantile of economic status and were predomi­ nantly residents of the capital area (Seoul Special City or Gyeonggi-do province). The time from the first date of the claim for each AILD (for AIH, PBC, and PSC) as a main or sub-diagnosis to the date of RID claim was 111 ± 381, 106 ± 367, 580 ± 955 days, respectively (data not shown). AILD prevalence and incidence by sex, age, and trend over time Patients with AIH and PBC were registered as RID since 2005, and those with PSC since 2014. In total, 10,212, 6,784, and 888 patients were diagnosed and claimed for AIH, PBC, and PSC during the study period, respectively (Supplementary Fig. 1).h The crude prevalence and incidence of AILD and tue number of AILD patients in 2019 are shown in Tables 2 and 3. The prevalence of AIH, PBC, and PSC was 18.4 (5.7 for males and 30.4 for females), 11.8 (3.7 for males and 19.8 for females), and 1.5 (1.5 for males and 1.5 for females) per 100,000 population, and the corresponding incidences were 2.3 (0.8 for males and 3.7 for females), 1.4 Table 2  The number of autoimmune liver disease patients and crude prevalence by age group per 100,000 population in 2019 Variables are shown as frequency (frequency per 100,000 population) Table 3  The number of newly diagnosed autoimmune liver disease patients and crude incidence by age group per 100,000 population in 2019 Variables are shown as frequency (frequency per 100,000 population)

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Inherited Pseudohypoaldosteronism, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Inherited Pseudohypoaldosteronism thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: NCC

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

The mechanism anchor is SLC12A3, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 16 registered studies.

• NCT06940856 — Chloride Imbalance in Preterm Infants; Recruiting; Not Applicable; sponsor Kanuni Sultan Suleyman Training and Research Hospital; enrollment 500.
• NCT06905600 — Transient Pseudohypoaldosteronism Affecting Children With Urinary Tract Malformation (TPHA); Unknown status; Not Applicable; sponsor Les Hopitaux Universitaires de Strasbourg; enrollment 50.
• NCT06838585 — Intra-Abdominal Sepsis and Relationship Between Cumulative Fluid Balance and Serum Sodium and Chloride Levels and In-Hospital Mortality; Completed; Not Applicable; sponsor not stated; enrollment 100.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate SLC12A3 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Inherited Pseudohypoaldosteronism merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Inherited Pseudohypoaldosteronism is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.